What coagulation studies should be obtained and how should abnormal results be managed in a patient with sepsis?

Coagulation Studies for Sepsis

In patients with sepsis, obtain platelet count and prothrombin time (PT/INR) as the essential coagulation studies, and do not routinely correct abnormal coagulation parameters unless the patient is actively bleeding or requires an invasive procedure.

Which Coagulation Studies to Obtain

The Surviving Sepsis Campaign guidelines 1, 2 and contemporary evidence 3, 4 support a focused approach to coagulation monitoring in sepsis:

Essential Studies

• Platelet count - Monitor for thrombocytopenia, which occurs in up to 66% of septic shock patients 5
• Prothrombin time (PT/INR) - Assesses coagulation factor depletion and helps calculate sepsis-induced coagulopathy (SIC) scores 3, 4

Optional Studies Based on Clinical Context

• Fibrinogen and D-dimer - While these can detect DIC, they are less useful for early detection because fibrinolysis is suppressed in sepsis, causing these markers to remain normal despite worsening coagulopathy 6
• SOFA score components - Required for calculating the SIC score, which uses platelet count, PT-INR, and SOFA score to identify early coagulopathy 3, 4

The SIC scoring system provides a practical framework: it assigns points based on platelet count (<150 × 10⁹/L = 1 point; <100 × 10⁹/L = 2 points), PT-INR (>1.2 = 1 point; >1.4 = 2 points), and SOFA score (≥1 = 1 point; ≥2 = 2 points). A score ≥4 indicates SIC and identifies patients at high risk for progression to overt DIC 3, 4.

Management of Abnormal Results

Fresh Frozen Plasma (FFP)

Do not transfuse FFP to correct laboratory coagulation abnormalities in non-bleeding patients, even if planning invasive procedures 1, 2. This is a weak recommendation with very low quality evidence, but the guidelines are consistent across multiple iterations. FFP transfusion typically fails to correct PT in non-bleeding patients with mild abnormalities and carries risks of volume overload and transfusion reactions 7.

Platelet Transfusion Thresholds

Use a tiered approach based on bleeding risk 1, 2:

• <10,000/mm³ (10 × 10⁹/L): Transfuse prophylactically in the absence of bleeding
• <20,000/mm³ (20 × 10⁹/L): Transfuse if significant bleeding risk exists
• ≥50,000/mm³ (50 × 10⁹/L): Target for active bleeding, surgery, or invasive procedures

These thresholds are based on consensus from chemotherapy-induced thrombocytopenia experience, recognizing that septic patients have both decreased platelet production and increased consumption 7.

Anticoagulant Therapy

Do not use antithrombin for treatment of sepsis and septic shock - this is a strong recommendation with moderate quality evidence 1, 2. High-dose antithrombin showed no mortality benefit and increased bleeding risk when combined with heparin 7.

No recommendation can be made regarding thrombomodulin or heparin for sepsis treatment 1, 2. However, emerging evidence suggests potential benefit in specific populations:

• Retrospective data indicates unfractionated heparin may reduce 28-day mortality in patients with SIC (36.4% control mortality vs 17.1% with heparin) without increasing serious hemorrhage 6
• Anticoagulant therapy (antithrombin or thrombomodulin) may improve mortality specifically in patients meeting SIC criteria, but not in those without SIC 6

Common Pitfalls to Avoid

1. Don't reflexively correct coagulation abnormalities - The presence of prolonged PT or low platelets does not automatically require correction unless bleeding or procedures are planned
2. Don't rely solely on fibrinogen/D-dimer - These markers have poor sensitivity for early septic coagulopathy due to suppressed fibrinolysis 6
3. Don't use anticoagulation routinely - Evidence for benefit remains controversial and should be considered only in selected high-risk patients with documented SIC 3
4. Don't forget VTE prophylaxis - While therapeutic anticoagulation is not routinely recommended, standard thromboprophylaxis remains appropriate unless contraindicated

Clinical Algorithm

1. Initial assessment: Obtain platelet count and PT/INR in all septic patients
2. Calculate SIC score if thrombocytopenia present (platelets <150 × 10⁹/L)
3. Monitor trends rather than single values - progressive thrombocytopenia or PT prolongation indicates worsening coagulopathy
4. Intervene based on bleeding status:
   • No bleeding + no procedures = observe, no transfusion
   • Active bleeding = transfuse per thresholds above
   • Planned invasive procedure = consider platelet transfusion if <50,000/mm³
5. Consider anticoagulation only in research settings or highly selected patients with documented SIC and institutional protocols

The evidence base remains limited, with most recommendations carrying low to very low quality evidence. The priority is treating the underlying infection while avoiding unnecessary blood product transfusions that provide no proven benefit and carry inherent risks 1, 2.